Senior Counsels Jason Drori and Simon Elliott contributed an article to IPPro Patents, “The PRICED Act: A Bold Attempt to Change the Biologics Market,” on August 17, 2016. The article examined the Price Relief, Innovation, and Competition for Essential Drugs (PRICED) Act proposed legislation that aims to reduce the market exclusivity period for new biologics from 12 to seven years in the United States. Drori and Elliott discussed how the PRICED Act may be a more direct threat to the biologics industry and risks upsetting a delicate balance.
Related Insights
June 12, 2025
Foley Career Perspectives
Foley Pride Month Program: Being an Active Ally in Tough Situations
In honor of Pride Month, Foley & Lardner welcomed back PFLAG National for the fifth year in a row to help us continue to advance in our…
June 12, 2025
Tariff & International Trade Resource
What Every Multinational Company Should Know About … Combating Fraud in India
Fraud continues to pose significant challenges across industries worldwide. For multinational companies operating in India, the country offers enormous opportunity — but also presents distinct operational and regulatory risks that require executive-level attention and strategic oversight.
June 11, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…